HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Endothelial exposure to hypoxia induces Egr-1 expression involving PKCalpha-mediated Ras/Raf-1/ERK1/2 pathway.

Abstract
Hypoxia induces endothelial dysfunction that results in a series of cardiovascular injuries. Early growth response-1 (Egr-1) has been indicated as a common theme in vascular injury. Here we demonstrates that in bovine aortic endothelial cells (ECs) subjected to hypoxia (PO(2) approximately 23 mmHg), rapidly increased Egr-1 mRNA expression which peaked within 30 min and decreased afterwards. Treatment of ECs with PD98059, a specific inhibitor to mitogen-activated protein kinase (MAPK/ERK), inhibited this hypoxia-induced Egr-1 expression. The involvement of ERK pathway was further substantiated by the inhibition of Egr-1 promoter activities when ECs were co-transfected with a dominant negative mutant of Ras (RasN17), Raf-1 (Raf 301), or a catalytically inactive mutant of ERK2 (mERK). In addition, the hypoxia-induced transcriptional activity of Elk-1, an ERK substrate, was abolished by administration of PD98059. Addition of calphostin C, a protein kinase C (PKC) inhibitor, completely blocked the hypoxia-augmented Egr-1 expression. The likewise occurred while exposing ECs to D609 to inhibit phospholipase C and BAPTA/AM to chelate intracellular calcium. Hypoxia to ECs increased ERK phosphorylation within 10 min and which was abolished by administration of PD98095, calphostin C, and BAPTA/AM. Hypoxia triggered a transient translocation of PKCalpha from cytosol to membrane fraction concurrent with the association of PKCalpha to Raf-1. Involvement of PKCalpha in mediating ERK activation was further confirmed by the inhibition of ERK and the subsequent Egr-1 gene induction with antisense oligonucleotides to PKCalpha. These results indicate that ECs under hypoxia induce Egr-1 expression and this induction requires calcium, phospholipase C activation, and PKCalpha-mediated Ras/Raf-1/ERK1/2 signaling pathway. Our finding support the importance of specific PKC isozyme linked to MAPK pathway in the regulation of endothelial responses to hypoxia.
AuthorsL W Lo, J J Cheng, J J Chiu, B S Wung, Y C Liu, D L Wang
JournalJournal of cellular physiology (J Cell Physiol) Vol. 188 Issue 3 Pg. 304-12 (Sep 2001) ISSN: 0021-9541 [Print] United States
PMID11473356 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright 2001 Wiley-Liss, Inc.
Chemical References
  • DNA-Binding Proteins
  • Enzyme Inhibitors
  • Isoenzymes
  • Proto-Oncogene Proteins
  • RNA, Messenger
  • Transcription Factors
  • ets-Domain Protein Elk-1
  • Proto-Oncogene Proteins c-raf
  • Protein Kinase C
  • Protein Kinase C-alpha
  • Mitogen-Activated Protein Kinase 1
  • Mitogen-Activated Protein Kinase 3
  • Mitogen-Activated Protein Kinases
  • Type C Phospholipases
  • ras Proteins
  • Calcium
Topics
  • Animals
  • Calcium (metabolism)
  • Cattle
  • Cell Hypoxia (physiology)
  • Cells, Cultured
  • DNA-Binding Proteins (biosynthesis, genetics)
  • Endothelium, Vascular (cytology, metabolism)
  • Enzyme Inhibitors (pharmacology)
  • Gene Expression Regulation (drug effects)
  • Genes, Dominant
  • Genes, Reporter
  • Isoenzymes (metabolism)
  • Mitogen-Activated Protein Kinase 1 (antagonists & inhibitors, genetics, metabolism)
  • Mitogen-Activated Protein Kinase 3
  • Mitogen-Activated Protein Kinases (antagonists & inhibitors, metabolism)
  • Protein Kinase C (metabolism)
  • Protein Kinase C-alpha
  • Proto-Oncogene Proteins (metabolism)
  • Proto-Oncogene Proteins c-raf (genetics, metabolism)
  • RNA, Messenger (metabolism)
  • Signal Transduction (drug effects, physiology)
  • Transcription Factors (biosynthesis, genetics)
  • Transcriptional Activation
  • Transfection
  • Type C Phospholipases (metabolism)
  • ets-Domain Protein Elk-1
  • ras Proteins (genetics, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: